Free Trial
NASDAQ:ENSC

Ensysce Biosciences (ENSC) Stock Price, News & Analysis

Ensysce Biosciences logo
$2.16 +0.07 (+3.35%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$2.15 -0.01 (-0.23%)
As of 07/11/2025 07:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Ensysce Biosciences Stock (NASDAQ:ENSC)

Key Stats

Today's Range
$2.00
$2.40
50-Day Range
$2.02
$2.55
52-Week Range
$1.62
$14.67
Volume
187,359 shs
Average Volume
952,414 shs
Market Capitalization
$5.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Ensysce Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
12th Percentile Overall Score

ENSC MarketRank™: 

Ensysce Biosciences scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Ensysce Biosciences.

  • Earnings Growth

    Earnings for Ensysce Biosciences are expected to decrease in the coming year, from ($8.33) to ($12.77) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Ensysce Biosciences is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Ensysce Biosciences is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Ensysce Biosciences has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Ensysce Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    12.49% of the float of Ensysce Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Ensysce Biosciences has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Ensysce Biosciences has recently decreased by 6.96%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Ensysce Biosciences does not currently pay a dividend.

  • Dividend Growth

    Ensysce Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.49% of the float of Ensysce Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Ensysce Biosciences has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Ensysce Biosciences has recently decreased by 6.96%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Ensysce Biosciences has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Ensysce Biosciences this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Ensysce Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 7.90% of the stock of Ensysce Biosciences is held by insiders.

  • Percentage Held by Institutions

    Only 5.63% of the stock of Ensysce Biosciences is held by institutions.

  • Read more about Ensysce Biosciences' insider trading history.
Receive ENSC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ensysce Biosciences and its competitors with MarketBeat's FREE daily newsletter.

ENSC Stock News Headlines

Ensysce Biosciences Inc News (ENSC) - Investing.com
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
Ensysce Flat on Receiving Grant
Ensysce Biosciences secures patent for OUD treatment
See More Headlines

ENSC Stock Analysis - Frequently Asked Questions

Ensysce Biosciences' stock was trading at $8.14 on January 1st, 2025. Since then, ENSC stock has decreased by 73.5% and is now trading at $2.16.

Ensysce Biosciences, Inc. (NASDAQ:ENSC) released its earnings results on Tuesday, May, 13th. The company reported ($1.39) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.02) by $1.63. The firm had revenue of $1.32 million for the quarter, compared to the consensus estimate of $0.65 million. Ensysce Biosciences had a negative net margin of 109.49% and a negative trailing twelve-month return on equity of 192.54%.

Shares of Ensysce Biosciences reverse split on Friday, March 31st 2023.The 1-12 reverse split was announced on Friday, March 31st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Shares of ENSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ensysce Biosciences investors own include Predictive Oncology (POAI), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), Meta Platforms (META), Insulet (PODD) and Broadcom (AVGO).

Company Calendar

Last Earnings
5/13/2025
Today
7/13/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ENSC
CIK
1716947
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($6.54)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$7.99 million
Net Margins
-109.49%
Pretax Margin
-109.49%
Return on Equity
-192.54%
Return on Assets
-121.77%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.50
Quick Ratio
2.50

Sales & Book Value

Annual Sales
$5.21 million
Price / Sales
0.98
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.59 per share
Price / Book
0.83

Miscellaneous

Outstanding Shares
2,370,000
Free Float
2,184,000
Market Cap
$5.12 million
Optionable
Not Optionable
Beta
0.98
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:ENSC) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners